Status:

COMPLETED

Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis - a Randomised Pilot Study

Lead Sponsor:

University Hospital Southampton NHS Foundation Trust

Collaborating Sponsors:

Imperial College London

St Mary's NHS Trust

Conditions:

Sepsis

Eligibility:

All Genders

3-14 years

Phase:

PHASE2

Brief Summary

Severe bacterial infections affecting multiple body organs, called severe sepsis (including meningococcal sepsis), remain an important cause of death and disability among children. Although early reco...

Detailed Description

1. PURPOSE: The Need for a Paediatric Trial of Steroids in Sepsis - potential benefits and risks Numerous targets for new therapies in sepsis have been identified, none of which have been shown to hav...

Eligibility Criteria

Inclusion

  • Severe sepsis where enrolment can occur within 20 hours of first contact with paediatric intensive care, or within 20 hours of the diagnosis of severe sepsis when this diagnosis is made on PICU. Randomisation should occur within 24 hours of first contact with paediatric intensive care, or within 24 hours of the diagnosis of severe sepsis when this diagnosis is made on PICU.
  • Requiring mechanical ventilation (The subjects must be mechanically ventilated for entry into the study but this is not time limited. It is routine practice at study centres to pre-emptively ventilate children with evolving sepsis)

Exclusion

  • Concomitant steroid therapy, vasopressor treatment \>24 hrs or use of etomidate (not recommended for use in children less than 10 years and selectively inhibits 11 beta-hydroxylase)
  • Patients who have a recognised indication for steroids
  • Other immunosuppressive/immunomodulatory therapy (not including intravenous immunoglobulin which is considered standard therapy in toxic shock syndrome and may be given for this indication)
  • Significant immunocompromise (eg HIV infection)
  • Advanced malignancy
  • Burns
  • Cardiopulmonary resuscitation
  • Children not likely to survive the time period of the maximum study intervention (5 days)
  • Patients who have undergone organ transplantation (including bone marrow transplantation)
  • Patients undergoing plasma exchange or whole blood exchange transfusion
  • Treatment with an investigational drug or device within the last 30 days prior to enrolment.
  • Patients who have experienced a prior episode of infection or sepsis during the current hospitalisation.
  • Patients who are pregnant (a pregnancy test will be carried out for females of 11 years and above as is standard practice for clinical trials).
  • Immediate families of investigators or site personnel directly affiliated with the study. Immediate family is defined as child or sibling, whether biological or legally adopted.

Key Trial Info

Start Date :

April 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2012

Estimated Enrollment :

21 Patients enrolled

Trial Details

Trial ID

NCT00732277

Start Date

April 1 2008

End Date

April 1 2012

Last Update

May 6 2016

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Bristol Royal Hospital for Children

Bristol, UK, United Kingdom, BS2 8BJ

2

Imperial College Healthcare NHS Trust

London, UK, United Kingdom, W2 1NY

3

Southampton University Hospitals NHS Trust

Southampton, UK, United Kingdom, SO16 6YD